Recent

% | $
Quotes you view appear here for quick access.

Organovo Holdings, Inc. Message Board

twojugglers 337 posts  |  Last Activity: 20 hours ago Member since: Apr 6, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Cell Biology Specialist Responsibilities:

    Partner closely with project team leads and scientists to prioritize relevant targets for release assays and identify/prioritize markers for use in phenotypic characterization.
    Lead efforts in the collection of data from cells grown in 2D, and partner closely with the analytical team to mine these data for possible predictors of 3D performance.
    Understand and become proficient in all steps of primary cell culture, bio-ink generation, bioprinting, and maintenance of bioprinted tissues after fabrication.
    Serve as bridge / liaison between tissue project teams and development teams and core functions (cell core, assay core, and histology core)
    Lead role as cell biologist in monitoring and troubleshooting active primary cell cultures, cell expansion/banking processes, cell harvests, and characterization experiments.,

    Sentiment: Strong Buy

  • Reply to

    Hockey stick

    by toppadred Jul 26, 2016 11:21 AM
    twojugglers twojugglers Jul 26, 2016 12:50 PM Flag

    Got it.Buy out.

    Sentiment: Strong Buy

  • Reply to

    Hockey stick

    by toppadred Jul 26, 2016 11:21 AM
    twojugglers twojugglers Jul 26, 2016 12:26 PM Flag

    Moo, what is that rumor?

    Sentiment: Strong Buy

  • Reply to

    Moving to the Nasdaq

    by twojugglers Jul 26, 2016 8:13 AM
    twojugglers twojugglers Jul 26, 2016 9:25 AM Flag

    Morning Bomba,

    You're right.

    Thanks,
    Juggsy

    Sentiment: Strong Buy

  • Reply to

    Moving to the Nasdaq

    by twojugglers Jul 26, 2016 8:13 AM
    twojugglers twojugglers Jul 26, 2016 9:17 AM Flag

    Found the listing requirements :

    1. $1,000,000 annual revenue
    2. $4.00. share price
    3. Market cap, $8,000,000

    Sentiment: Strong Buy

  • Reply to

    Moving to the Nasdaq

    by twojugglers Jul 26, 2016 8:13 AM
    twojugglers twojugglers Jul 26, 2016 9:07 AM Flag

    announced that it will move its stock exchange listing to the NASDAQ Stock Market from the NYSE MKT. The Company expects its common stock will begin trading on the NASDAQ Global Market on August 8, 2016, and its shares will continue to trade under the “ONVO” ticker symbol. Organovo’s common stock will continue to trade on the NYSE MKT until the market close on August 5, 2016.uh

    Don't see how you can move your listing to Nasdaq without meeting their listing requirements.

    Sentiment: Strong Buy

  • Reply to

    Moving to the Nasdaq

    by twojugglers Jul 26, 2016 8:13 AM
    twojugglers twojugglers Jul 26, 2016 8:49 AM Flag

    Would like to see how we met those listing requirements.

    Sentiment: Strong Buy

  • twojugglers by twojugglers Jul 26, 2016 8:13 AM Flag

    Nice move.

    Sentiment: Strong Buy

  • Reply to

    Motley fool write-up

    by davemaltese1 Jul 12, 2016 6:21 PM
    twojugglers twojugglers Jul 12, 2016 8:15 PM Flag

    I find this comment odd and indefensible:

    "At first glance, the publication from Organovo's and Roche's research doesn't seem like such a big deal. For Roche, it isn't."

    Really? Saving millions of $$$ plus a few lives isn't such a big deal???

    I beg to differ.

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 12, 2016 6:55 AM Flag

    At 3d-tissuemodels dot com/

    Thanks Z. Great post.

    This program couldn't be more perfectly designed to highlight and promote the adoption of Organovo's ExVive3d tissues.

    "3D tissue models are being heralded to reduce and replace the use of classical in-vitro and animal models within pharmaceutical research as they promise to accelerate validation of target molecules, expedite time to the clinic, and reduce attrition rates and the cost to bring drugs to market.

    These models provide more physiologically relevant models enabling the use of human tissue earlier in the pipeline. However, despite the recent breakthroughs, key concerns around reproducibility, validity and standardization still remain to be addressed before further advances can be made.

    3D Tissue Models 2016 will bring together leaders across industry and academia who are already pushing the boundaries with this technology. Through a case-study driven agenda, you will learn to tackle these challenges from early adopters within the industry. This is your chance to:

    Identify practical applications and the utility of 3D microphysiological models to help you maximize the discovery and development of drugs within translational and preclinical research
    Understand where 3D microphysiological systems have been validated and qualified as predictive models for drug safety and efficacy
    Engage with your peers and industry leaders across 2 days of interactive networking sessions
    Identify the latest advances in 3D Culturing and how to best implement them to enrich your pipeline
    Realize the potential of 3D microphysiological systems as more effective and predictive in-vitro tools in the drug development
    Elucidate bio-computational strategies utilizing complex 3D systems to increase predictability and translatability to the clinic.
    Understand how to overcome the remaining barriers for pharma to truly adopt and implement these systems across the board
    Receive an insight into how to approach designing and enginee

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 11, 2016 6:04 PM Flag

    Hope you're right about that, but if not, sooner or later this company and the share price will prevail.

    Sentiment: Strong Buy

  • Reply to

    Certified superior results from Roche

    by lfescience Jul 11, 2016 9:19 AM
    twojugglers twojugglers Jul 11, 2016 9:32 AM Flag

    Gosh, it seems like a long time ago now that Organovo passed out their new liver assays to a number of Key Opinion Leaders. We were just on the edge of our seats waiting to hear how they liked working with ExVive3d Liver tissues. We then got word that one of the researchers was so excited that he wanted to jump ahead and present data at an upcoming conference. We knew at that point we had a winner. So this paper grew out of that and is a great validation for this little company of ours. I'm so proud and pleased.....

    Sentiment: Strong Buy

  • twojugglers twojugglers Jul 10, 2016 10:24 AM Flag

    Good article, especially helps to illustrate the need for effective kidney cancer treatments.

    Sentiment: Strong Buy

  • February 26, 2015
    Dear Fellow Shareholder,
    It’s always a pleasure when I get to provide an update on Organovo, because of our steady and
    exciting movement forward. Our progress has recently been recognized by Organovo being
    named as one of FastCompany’s Top 10 Most Innovative Companies of 2015 in Health Care
    and covered in an article in the Wall Street Journal.

    As you know, most importantly, we reported in February 2015 the first ever revenues from a 3D Bioprinted commercial tissue, our exVive3D Liver, Bioprinted Human
    Tissue. The liver has a nice tailwind behind it, and we believe it has a strong commercial future
    in front of it. As we’ve said before, we believe that as we penetrate the toxicology market, the
    liver product and service will grow into the tens of millions in annual revenue, and has $100M+
    revenue potential in the future as we pursue diligent sales and marketing efforts over time (inside
    of a total addressable market of over $1B). We believe we’re on the way to building a strong
    profit center in research tissues for Organovo, which will expand with our launch of 3D
    bioprinted kidney tissues in 2016. But, the most important thing that the successful launch of
    this first product represents, in our opinion, is a validation of our 3D Bioprinting platform
    overall.

    Sentiment: Strong Buy

  • Reply to

    I cannot believe the Motley Article

    by dd4554 Jul 8, 2016 6:03 PM
    twojugglers twojugglers Jul 8, 2016 7:48 PM Flag

    One year anniversary last month. Shoulder is back to normal. Very pleased. Thanks for asking.

    Sentiment: Strong Buy

  • Reply to

    I cannot believe the Motley Article

    by dd4554 Jul 8, 2016 6:03 PM
    twojugglers twojugglers Jul 8, 2016 7:30 PM Flag

    Reilly,
    Welcome back! Sorry you got hurt.....

    Sentiment: Strong Buy

  • Reply to

    I cannot believe the Motley Article

    by dd4554 Jul 8, 2016 6:03 PM
    twojugglers twojugglers Jul 8, 2016 7:28 PM Flag

    Did you finally buy in today gpls?

    Sentiment: Strong Buy

  • Reply to

    Something is suspect?

    by bottomfisher0 Jul 8, 2016 4:55 PM
    twojugglers twojugglers Jul 8, 2016 6:22 PM Flag

    You saying the CEO left is a lot like Donald Trump telling the Republican congressmen that he loves and supports the 12th article of the US Constitution.

    Sentiment: Strong Buy

  • Reply to

    I cannot believe the Motley Article

    by dd4554 Jul 8, 2016 6:03 PM
    twojugglers twojugglers Jul 8, 2016 6:19 PM Flag

    Couldn't agree with you more. Well said.

    Sentiment: Strong Buy

  • Published yesterday in Plos One:

    Deborah G. Nguyen , Juergen Funk, Justin B. Robbins, Candace Crogan-Grundy, Sharon C. Presnell, Thomas Singer, Adrian B. Roth

    Abstract

    Modeling clinically relevant tissue responses using cell models poses a significant challenge for drug development, in particular for drug induced liver injury (DILI). This is mainly because existing liver models lack longevity and tissue-level complexity which limits their utility in predictive toxicology. In this study, we established and characterized novel bioprinted human liver tissue mimetics comprised of patient-derived hepatocytes and non-parenchymal cells in a defined architecture. Scaffold-free assembly of different cell types in an in vivo-relevant architecture allowed for histologic analysis that revealed distinct intercellular hepatocyte junctions, CD31+ endothelial networks, and desmin positive, smooth muscle actin negative quiescent stellates. Unlike what was seen in 2D hepatocyte cultures, the tissues maintained levels of ATP, Albumin as well as expression and drug-induced enzyme activity of Cytochrome P450s over 4 weeks in culture. To assess the ability of the 3D liver cultures to model tissue-level DILI, dose responses of Trovafloxacin, a drug whose hepatotoxic potential could not be assessed by standard pre-clinical models, were compared to the structurally related non-toxic drug Levofloxacin. Trovafloxacin induced significant, dose-dependent toxicity at clinically relevant doses (≤ 4uM). Interestingly, Trovafloxacin toxicity was observed without lipopolysaccharide stimulation and in the absence of resident macrophages in contrast to earlier reports. Together, these results demonstrate that 3D bioprinted liver tissues can both effectively model DILI and distinguish between highly related compounds with differential profile. Thus, the combination of patient-derived primary cells with bioprinting technology here for the first time demonstrates superior performance in terms of mimic

    Sentiment: Strong Buy

ONVO
4.25+0.05(+1.19%)2:51 PMEDT